Ayrmid has announced significant advancements in the use of motixafortide for mobilizing hematopoietic stem cells (HSCs) in patients suffering from sickle cell disease and beta-thalassemia. This new data indicates that motixafortide could facilitate quicker access to gene therapies, with a notable 73% of participants achieving adequate HSC collection necessary for treatment.
During recent presentations at TANDEM 2026, the company reported that out of 15 patients, 11 successfully mobilized sufficient HSCs to progress to gene therapy manufacturing. This is particularly significant as these patients had previously failed to collect adequate cells using plerixafor, a standard mobilizing agent. Among those who collected sufficient cells, five patients received their gene therapy and experienced appropriate engraftment.
Ayrmid’s findings highlight the effectiveness of motixafortide as a standalone mobilizing agent for individuals with sickle cell disease. Additionally, when used in conjunction with granulocyte-colony stimulating factor (G-CSF), it shows promise for patients with beta-thalassemia.
The study’s results underscore the potential of motixafortide in transforming treatment protocols for these blood disorders, providing new hope for patients who have faced challenges with previous mobilization therapies. The data not only supports the use of motixafortide but also opens avenues for further research into optimizing stem cell mobilization strategies.
As gene therapies continue to evolve, Ayrmid’s progress in stem cell mobilization may represent a critical step forward in the treatment of sickle cell disease and beta-thalassemia, potentially improving outcomes for patients around the world.
